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Abstract
While tumor genome sequencing has become widely available in clinical and research settings, the interpretation
of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a
versatile platform that automates the interpretation of newly sequenced cancer genomes, annotating the potential
of alterations detected in tumors to act as drivers and their possible effect on treatment response. The results are
organized in different levels of evidence according to current knowledge, which we envision can support a broad
range of oncology use cases. The resource is publicly available at http://www.cancergenomeinterpreter.org.
Background
The accumulation of so-called “driver” genomic alter-
ations confers on cells tumorigenic capabilities [1].
Thousands of tumor genomes are sequenced around the
world every year for both research and clinical purposes.
In some cases the whole genome is sequenced while in
others the focus is on the exome or a panel of selected
genomic regions. It then becomes necessary to annotate
which of the somatic mutations identified by the sequen-
cing have a possible role in tumorigenesis and treatment
response. This process, which we refer to as “the inter-
pretation of cancer genomes”, is currently tedious and
largely unsolved. One of its major bottlenecks is the
identification of the alterations driving the tumor. A
widely employed approach to solve this hurdle consists
in focusing on the mutations affecting known cancer
genes, i.e., tumor suppressors and oncogenes. These
were initially identified through experimentation, giving
rise over the past 40 years to a stable census of human
cancer genes [2]. More recently, projects re-sequencing
large cohorts of tumors have provided the opportunity
to systematically identify genes involved in tumorigen-
esis through the detection of signals of positive selection
in their alteration patterns across tumors of some two
dozen malignancies [3–6]. However, many of the som-
atic variants detected in tumors, even those in cancer
genes, still have uncertain significance and thus it is not
clear whether or not they are relevant for tumorigenesis.
Another hurdle in the interpretation of cancer genomes
concerns one of its crucial aims: the identification of
tumor alterations that may affect treatment options. Un-
structured information on the effectiveness of therapies
targeting specific cancer drivers is continuously generated
by clinical trials and pre-clinical experiments, and cur-
rently several resources are dedicated to gather and curate
these data, such as ClinVar [7], DoCM [8], OncoKB [9],
My Cancer Genome (https://www.mycancergenome.org),
PMKB [10], PCT (https://pct.mdanderson.org), CIViC
[11], and JAX-CKB (https://ckb.jax.org). Nevertheless,
none of these resources address the whole process of in-
terpretation and researchers and clinicians thus face a
challenging task to annotate the variants detected in a
newly sequenced cancer genome with their collective
information.
Here, we describe the Cancer Genome Interpreter
(CGI), a platform that systematizes the interpretation of
cancer genomes, the main hallmark of which is the
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streamlining and automatization of the whole process
(Additional file 1: Table S1). Specifically, the CGI ad-
dresses the two aforementioned challenges. On the one
hand, it identifies all known and likely tumorigenic
genomic alterations (point mutations, small insertions/
deletions, copy number alterations and/or gene fusions)
of a newly sequenced tumor, including the assessment of
variants of unknown significance. On the other, it anno-
tates all variants of the tumor that constitute state-of-
the-art biomarkers of drug response organized using
different clinical evidence. The CGI accepts several data
formats and its output reports are provided in a user-
friendly interactive framework that organizes the results
according to distinct levels of clinical relevance, which
may thus be used in a broad range of applications.
Construction and content
The CGI employs existing or newly developed re-
sources and computational methods to annotate and
analyze the alterations in a tumor according to dis-
tinct levels of evidence (Fig. 1a; details in Additional
file 2: Note I). The tool is freely available through an
API or a web interface at http://www.cancergen-
omeinterpreter.org, under an open license, with the
aim of facilitating its use by cancer researchers and
clinical oncologists (Fig. 1b–d). In the following sec-
tions we present the blueprint for the interpretation
of cancer genomes implemented by the CGI, describe
the resource, and discuss its utility.
A comprehensive catalog of cancer genes across tumor
types
One of the main aims of the interpretation of cancer ge-
nomes is to identify the alterations responsible for tumori-
genic traits. In the CGI, this process begins with a focus on
alterations that affect the genes capable of driving the
cancer hallmarks of a particular tumor type. Therefore, we
compiled a catalog of genes involved in the onset and pro-
gression of different types of cancer, obtained via different
methods and from different sources (Additional file 2: Note
II). First, from manually curated resources [2, 7, 8, 12, 13]
and the literature we collected genes that have been experi-
mentally or clinically verified to drive tumorigenesis.
Second, we incorporated the results of bioinformatics
a b
c
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Fig. 1 Cancer Genome Interpreter. a Outline of the CGI workflow. With a list of genomic alterations as input, the CGI automatically recognizes the
format, remaps the variants as needed, and standardizes the annotation for downstream compatibility. All analyses are cancer-specific and thus
the tumor type of the sample(s) to analyze is also required. Next, the CGI identifies known driver alterations and annotates and classifies the
remaining variants of unknown significance. Finally, alterations that are biomarkers of drug effects are identified. b The CGI may be run via the web at
http://www.cancergenomeinterpreter.org (left panel) or through an API. The web results can be stored in a private repository (right panel) for their management.
The results of the CGI are provided via interactive reports. c An example of a mutation analysis report. This contains the annotations of all mutations, which
empowers the user’s review, and the labels for those known or predicted to be drivers by OncodriveMUT. d An example of a biomarker match report. This
contains the putative biomarkers of drug response found in the tumor organized according to distinct levels of clinical relevance. All these web reports are
interactive and configurable by the user. CNA copy number alteration
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analyses of large tumor cohorts re-sequenced by inter-
national initiatives such as The Cancer Genome Atlas
(http://cancergenome.nih.gov/abouttcga) and the Inter-
national Cancer Genome Consortium [14] (specifically,
we identified genes whose somatic alterations exhibit
signals of positive selection across 6729 tumors repre-
senting 28 types of cancer [4]). Each of these cancer
genes was annotated with their mode of action in
tumorigenesis (i.e., whether they function as oncogenes
or tumor suppressors), on the basis of either experi-
mentally verified sources, or in silico prediction [15]. The
resulting Catalog of Cancer Genes currently comprises
837 genes with evidence of a tumorigenic role in 193
different cancer types (Fig. 2a). Each entry in the catalog
thus includes, along with the name of the driver gene,
(i) the malignancies it drives, organized according to
available evidence; (ii) the types of alterations involved
(mutations, copy number alterations, and/or gene
translocations); (iii) the source(s) of this information;
(iv) the context (germline or somatic) in which these
alterations are tumorigenic; and (v) the gene’s mode
of action in cancer as appropriate. The catalog is
available for download through the CGI website
(https://www.cancergenomeinterpreter.org/genes).
Most mutations affecting cancer genes are of uncertain
significance
The focus on cancer genes described above is a neces-
sary but not sufficient to identify the tumorigenic vari-
ants in a tumor, since not all variants observed in a
cancer gene are necessarily capable of driving tumori-
genesis. Therefore, the CGI next focuses on annotating
and analyzing protein-affecting mutations (PAMs) that
occur in genes of the Catalog of Cancer Genes. First, val-
idated tumorigenic mutations may confidently be labeled
as drivers when detected in a newly sequenced tumor.
We compiled an inventory that currently contains 5314
such validated mutations, including cancer-predisposing
variants, from dedicated resources [7–9, 12, 13, 16] and
the literature (Fig. 2b; Additional file 2: Note III). This
Catalog of Validated Oncogenic Mutations is available
for download through the CGI website (https://www.
cancergenomeinterpreter.org/mutations). Across a pan-
cancer cohort of 6792 tumors sequenced at the whole-
exome level (mostly at diagnosis) [4] we observed that
only 5360 (916 unique variants) of the 44,601 PAMs found
in cancer genes appear in this catalog. In other words,
88% of all PAMs that affect cancer genes in this cohort are
currently of uncertain significance for tumorigenesis, a
a
c
b
d
Fig. 2 Annotating mutations in cancer genes. a Catalog of Cancer Genes. Genes that drive tumorigenesis via mutations, copy number alterations,
and/or translocations are annotated with their mode of action (MoA). b Catalog of Validated Oncogenic Mutations. Clinically or experimentally
validated driver mutations were gathered from manually annotated resources and the cancer literature. c Proportion of validated mutations
observed across the cancer genes of 6792 tumors. Cancer types: ALL acute lymphocytic leukemia, AML acute myeloid leukemia, BLCA bladder
carcinoma, BRCA breast carcinoma, CLL chronic lymphocytic leukemia, CM cutaneous melanoma, COREAD colorectal adenocarcinoma, DLBC
diffuse large B cell lymphoma, ESCA esophageal carcinoma, GBM glioblastoma multiforme, HC hepatocarcinoma, HNSC head and neck squamous
cell carcinoma, LGG lower grade glioma, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, MB medulloblastoma, MM multiple
myeloma, NB neuroblastoma, NSCLC non-small cell lung carcinoma, OV serous ovarian adenocarcinoma, PA pilocytic astrocytoma, PAAD pancreas
adenocarcinoma, PRAD prostate adenocarcinoma, RCC renal clear cell carcinoma, SCLC small cell lung carcinoma, STAD stomach adenocarcinoma,
THCA thyroid carcinoma, UCEC uterine corpus endometrioid carcinoma. d OncodriveMUT schema to estimate the oncogenic potential of the
variants of unknown significance. A set of heuristic rules combines the annotations obtained for a given mutation with the knowledge about the
genes (or regions thereof) in which it is observed, as retrieved from the computational analyses of sequenced cohorts
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proportion that varies widely per gene and tumor type
(Fig. 2c; Additional file 2: Note VII). It is therefore crucial
to assess the tumorigenic potential of these variants, espe-
cially when they affect genes that are—or may be—thera-
peutic targets. We reasoned that several features of each
specific mutation as well as of the genes they affect could
help address this question. Moreover, we propose that
some of these features of interest can be extracted from
the analyses of large sequenced cohorts of healthy and
tumor tissue [4, 17]. Examples of relevant attributes in-
clude the following: i) the mode of action of the gene in
the cancer type (oncogene or tumor suppressor); ii) the
consequence type of the mutation (e.g., synonymous, mis-
sense, or truncating); iii) its position within the transcript;
iv) whether it falls in a mutational hotspot or cluster; v) its
predicted functional impact; vi) its frequency within the
human population; and vii) whether it occurs in a domain
of the protein that is depleted of germline variants. The
CGI assesses the tumorigenic potential of the variants of
unknown significance via OncodriveMUT, a newly devel-
oped rule-based approach that combines the values of
these features (Fig. 2d; Additional file 2: Note IVa). We
assessed the performance of OncodriveMUT in the task
of classifying driver and passenger mutations, using the
Catalog of Validated Oncogenic Mutations (n = 5314) and
a collected set of likely neutral—i.e., non-tumorigenic—
PAMs affecting cancer genes (n = 1676). We found that
OncodriveMUT separated the variants of these two data
sets with 86% accuracy (Matthews correlation coefficient,
0.64), out-performing other methods employed for this
goal (Additional file 2: Note IVb). In addition, for several
features, the variants classified as drivers by Oncodrive-
MUT followed the trend expected for oncogenic muta-
tions (e.g., they exhibited larger clonal fractions among all
mutations in cancer genes), and OncodriveMUT’s predic-
tions on a set of recently probed uncommon cancer muta-
tions exhibited a high concordance with experimental
evidence [18–21] (Additional file 2: Note IVb). Of note,
the attributes employed by OncodriveMUT to classify
each variant are detailed in the CGI output, which facili-
tates the user’s review of the results. In summary, the CGI
annotates the mutations affecting cancer genes with fea-
tures relevant to their potential role in cancer, identifying
validated oncogenic events and identifying the most likely
drivers among the variants of unknown significance.
A database of genomic determinants of anti-cancer drug
response
The second major aim of the effort to interpret cancer
genomes is to identify which tumor alterations may
shape the response to anti-cancer therapies. Knowledge
on the influence of genomic alterations on drug response
is continuously generated and reported through publica-
tions, clinical trials, and conference communications.
Nevertheless, collecting and curating relevant information
into an easy-to-use resource supporting the comparison
with newly sequenced tumors and organize the results
according to the needs of different users is challenging.
The CGI employs two resources to explore the associa-
tions between gene alterations and drug response. The
first is the Cancer Biomarkers database, an extension of a
previous collection of genomic biomarkers of anti-cancer
drug response [12] which currently contains information
on 1624 genomic biomarkers of response (sensitivity,
resistance, or toxicity) to 310 drugs across 130 types of
cancer. Negative results of clinical trials, e.g., the unsuc-
cessful use of BRAF V600 inhibitors as a single thera-
peutic agent in colorectal cancers bearing that mutation,
are also included in the database. Importantly, these bio-
markers are organized according to the level of clinical
evidence supporting each one, ranging from results of
pre-clinical data, case reports, and clinical trials in early
(I/II) and late phases (III/IV) to standard-of-care guide-
lines. The database is continuously updated by a board of
medical oncologists and cancer genomics experts (Fig. 3a;
Additional file 2: Note V). As explained in the “Introduc-
tion”, the Cancer Biomarkers database is only one of the
resources currently annotating the biomarkers of tumor
response to drugs (Additional file 1: Table S1). The leading
institutions developing these knowledgebases were re-
cently integrated into the Variant Interpretation for
Cancer Consortium (http://cancervariants.org/) under the
umbrella of the Global Alliance for Genomics & Health
[22]. Besides the aggregation of the data collected by each
individual resource, the aim of this project will be to
establish community standards to represent and share this
information.
The second resource is the Cancer Bioactivities data-
base, which currently contains information on 20,243
chemical compound–protein product interactions that
may support novel research applications. We built this
database by compiling a catalog of available results from
bioactivity assays of small molecules interacting with can-
cer proteins. This information was obtained by querying
several external databases (Additional file 2: Note VI). The
CGI matches the alterations observed in newly sequenced
tumors to the biomarkers or target genes in these two
databases. This process supports the identification of bio-
markers at different levels of gene resolution, ranged from
variants affecting a gene region to specific amino acid
changes. Of note, the CGI also reports co-occurring alter-
ations that affect the response to a given treatment as ap-
propriate. This includes the co-existence of biomarkers of
resistance and sensitivity to the same drug, and bio-
markers of drug sensitivity that depend upon simultan-
eous genomic events. In summary, these two databases
constitute comprehensive repositories of genome-guided
therapeutic actionability in cancer according to current
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supporting evidence. Both resources are available for
download through the CGI website (https://www.cancer
genomeinterpreter.org/biomarkers, https://www.cancerge
nomeinterpreter.org/bioactivities).
Utility and discussion
The CGI (and the databases created to support its
implementation) are distributed under an open li-
cense, and the resource can be accessed via its web
a b
c d
Fig. 3 Cancer Biomarkers Database. a A board of clinical and research experts gather the genomic biomarkers of drug response to be included in the
Cancer Biomarkers database through periodic updates. The upper panel displays the simplified schema of the data model. The clinical/research
community is encouraged to provide feedback to edit an existing entry or add a novel one by using the comment feature available in the web service.
Any suggestion is subsequently evaluated by the scientific team and incorporated as appropriate. A semi-automatic pipeline annotates any novel entry
to ensure the consistency of the attributes, including variant re-mapping from protein to genomic coordinates when necessary. The lower panel displays
some of the 1574 biomarkers that have been collected in the current version of the database, and the pie charts summarize the content. CNA copy
number alteration. b CGI analyses detect putative driver mutations in individual tumors that are rarely observed in the corresponding cancer type. When
these variants are known targets of anti-cancer therapies, they may constitute tumor type re-purposing opportunities. The graph summarizes some of
these potential opportunities detected by the CGI on 6792 pan-cancer tumors with exome-sequencing data, which are currently unexplored. The
barplots display the overall number of tumor samples (separated by cancer type) in which they were observed. The acronym of the cancer type in which
the genomic event is demonstrated to confer sensitivity to the drug is shown in parentheses following the name of the drug, and the
clinical evidence of that association is represented through color circles (note that the clinical guidelines/recommendations label refers to
FDA-approved or international guidelines). Targeted drugs and chemotherapies are shown separately. Cancer acronyms that are not
included in the Fig. 2 legend: RA renal angiomyolipoma, BCC basal cell carcinoma, GCA giant cell astrocytoma, G glioma, MCL mantle cell
lymphoma, MRT malignant rhabdoid tumor, R renal, CH chollangiocarcinoma. c Therapeutic landscape of 6792 tumors with exome-sequencing data.
Fraction of tumors with genomic alterations that are biomarkers of drug response in each cancer type. Colors in the bars denote the clinical evidence
supporting the effect of biomarkers in that disease (see evidence colors in b). Note that the event with evidence closest to the clinical evidence is
given priority when several biomarkers of drug response co-occur in the same tumor sample. The lower part of the graph indicates the total number
of samples per cancer type, detailing the number of samples in which mutation, CNA, and/or fusion data were analyzed. Cancer acronyms as in the
Fig. 2 caption. d Same as c for a cohort of 17,462 tumors sequenced by targeted panels and gathered by the GENIE project. Tumors were grouped
according to the most specific disease subtype available in the patient information. Cancer acronyms that are not included in the Fig. 2 legend are
detailed in Additional file 2: Supplementary content
Tamborero et al. Genome Medicine  (2018) 10:25 Page 5 of 8
site at https://www.cancergenomeinterpreter.org and
through an Application Programming Interface (API;
Additional file 2: Notes Ic and Id). The use of the CGI
to automatically interpret cancer genomes has broad
potential applications, ranging from basic cancer gen-
omics to the translational research setting. One fea-
ture of the CGI that makes it particularly suitable for
different types of applications is its usability. The user
can input the tumor alterations to be analyzed by
uploading files following different standards and/or by
typing them in a free-text box. The system is prepared
to automatically recognize and re-map as necessary [23]
different formats, such as genomic, transcript, or protein-
based coordinates for mutations [23] (Additional file 2:
Note Ib). The use of the CGI can help addressing ques-
tions raised in different oncology research settings. A
newly sequenced group of tumors may be readily inter-
preted, and systematic analyses of large sample sets are
supported as exemplified with the 6729 pan-cancer cohort
presented in this article. The application of the CGI to the
mutations profiled across the whole exomes of these
tumors delivered a catalog of putative driver alterations
across its 28 cancer types (made available through http://
www.intogen.org; Additional file 2: Note VII). The poten-
tial of a comprehensive analysis of individual alterations is
illustrated by the identification of uncommon events in a
tumor cohort that may be exploited by drug re-purposing
opportunities (Fig. 3b; Additional file 2: Note VII). Overall,
the CGI identified 5.2 and 3.5% of the tumors with gen-
omic alterations that are biomarkers of drug response
used in the clinical practice (FDA-approved or inter-
national guidelines) or reported in late phase (III–IV) clin-
ical trials, respectively. When considering biomarkers
supported by lower levels of clinical relevance, a total of
62% of the tumors exhibited at least one biomarker with
increased response to an anti-cancer drug according to
findings in early clinical trials, case reports, or pre-clinical
assays. These numbers varied greatly across tumor types,
partially explained by the relevance of cancer-recurrent
alterations in shaping the response to drugs, such as
inhibitors of the BRAF V600 mutated form in cutaneous
melanoma (clinical guidelines), certain chemotherapies
administered for DNMT3A or NPM1 mutant acute mye-
loid leukemias (clinical guidelines), PIK3CA mutation in-
hibitors in breast cancer (early clinical trial results [24]),
and WEE1 inhibitors in TP53 mutated ovary tumors
(early clinical trial results [25]) (Fig. 3c; Additional file 2:
Note VII). However, this cohort mostly includes samples
sequenced at diagnosis and thus they may not reflect the
type of tumors that are evaluated by molecular oncol-
ogy boards at present. We therefore also applied the
CGI to the sequencing data of 17,642 tumors recently
released by the GENIE project, which profiled more
clinically advanced cancers using targeted panels [26].
The CGI identified a larger percentage of tumors bearing
potential actionable genomic alterations in that cohort.
Specifically, 8 and 6% of GENIE tumors exhibited bio-
markers of drug response used in clinical practice or re-
ported in late clinical trials, and overall 72% of these
tumors exhibited at least one alteration reported as a bio-
marker of drug response supported by any level of clinical
evidence (including pre-clinical data; Fig. 3d; Additional
file 2: Note VII). These percentages do not include cases
in which a tumor exhibits co-occurring alterations that
confer resistance to a given drug, in which the therapy
was not in silico prescribed accordingly. Of note, the
GENIE cohort exhibited a larger number of genomic bio-
markers of drug resistance (to both targeted therapies and
immune checkpoint blockade agents), as expected of
tumors with a higher proportion of recurrence/relapse pa-
tients (Additional file 2: Note VII). These analyses provide
a comprehensive state-of-the-art snapshot of the putative
genomic drivers of cancer and the landscape of genomic-
guided therapies according to our current knowledge. In
addition, the application of the CGI to analyze the results
of drug responses observed in tumors with different
genomic architecture can facilitate the discovery of novel
genomic biomarkers of drug sensitivity or resistance. The
distinction between driver and passenger events recently
contributed to the development of better predictive
models to identify novel genomic markers of drug re-
sponse in cancer cell lines [27].
In previous examples, the systematic analysis of large
datasets was facilitated by the automatic classification of
cancer variants that CGI provides. However, the detailed
review of these results is empowered by the inclusion in
the output reports of all the annotations employed by
the CGI. The ability to review these data is especially
critical in the clinical research setting. In this case, the
use of the CGI to analyze the list of alterations de-
tected in a patient’s tumor could support decision-
making in multiple scenarios, assessing variants of
unknown significance that may have implications for
response to therapy. Early clinical adopters of the CGI
have used the resource to support final decisions
about the most appropriate genomic-guided clinical
trial to enroll cancer patients or explore potential drug
re-purposing opportunities for pediatric tumors unre-
sponsive to standard-of-care therapy (see these use
cases in Additional file 2: Note VIII).
Crucial to the performance of the CGI are the mainten-
ance and further development of its two distinct types of
resources: the repositories of accumulated knowledge,
which are continuously generated, and the bioinformatics
methods to estimate the relevance of those events that are
not yet validated. As new tumor cohorts are re-sequenced
and analyzed, more comprehensive catalogs of cancer
genes and oncogenic mutations will be obtained, including
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both new malignancies and new genomic elements. In
particular, the possibility to identify non-coding cancer
drivers [28] from currently generated whole-genome se-
quencing data will open up the opportunity to explore the
actionability of non-coding genomic alterations (https://
dcc.icgc.org/pcawg). With respect to the aggregation,
curation, and interpretation of the relevance of cancer var-
iants, our team follows the standard operating procedures
developed under the umbrella of the H2020 MedBioinfor-
matics (http://www.medbioinformatics.eu/) project, thus
ensuring the mid-term maintenance of these resources.
Feedback from the community is also facilitated through
the CGI web interface. Access to this type of cancer data
is crucial for the advance of precision medicine, but is
highly complex for a single institution to comprehensively
manage and update. We envision that individual databases
will continue to be maintained to fulfill specific needs
[11], but our long-term impact will largely rely, first, on
the establishment of international standards for the collec-
tion of data relevant to associations between cancer vari-
ants and clinical outcomes and, second, on our collective
success in encouraging the community to share and
harmonize such knowledge.
Conclusions
The CGI is a versatile platform that automates the steps
proposed here for the interpretation of cancer genomes.
It annotates the alterations detected in human tumors
with features that may inform about their involvement
in tumorigenesis. It also highlights the alterations of the
tumor that constitute biomarkers of response to anti-
cancer drugs, according to current levels of evidence.
The CGI is easy to use, and will improve with new
knowledge extracted from the study of thousands of
tumors. We envision that it will become established as a
useful tool in both the basic and translational cancer re-
search settings.
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